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ARTICLE
Comparison of participant information and informed
consent forms of five European studies in genetic
isolated populations
Deborah Mascalzoni*,1, A Cecile JW Janssens2, Alison Stewart3, Peter Pramstaller1, Ulf Gyllensten4,
Igor Rudan5,6, Cornelia M van Duijn2, James F Wilson6, Harry Campbell6 and Ruth Mc Quillan6
on behalf of the EUROSPAN consortium
Family-based research in genetically isolated populations is an effective approach for identifying loci influencing variation in
disease traits. In common with all studies in humans, those in genetically isolated populations need ethical approval; however,
existing ethical frameworks may be inadequate to protect participant privacy and confidentiality and to address participants’
information needs in such populations. Using the ethical–legal guidelines of the Council for International Organizations of
Medical Sciences (CIOMS) as a template, we compared the participant information leaflets and consent forms of studies in five
European genetically isolated populations to identify additional information that should be incorporated into information leaflets
and consent forms to guarantee satisfactorily informed consent. We highlight the additional information that participants require
on the research purpose and the reasons why their population was chosen; on the potential risks and benefits of participation;
on the opportunities for benefit sharing; on privacy; on the withdrawal of consent and on the disclosure of genetic data. This
research raises some important issues that should be addressed properly and identifies relevant types of information that should
be incorporated into information leaflets for this type of study.
European Journal of Human Genetics (2010) 18, 296–302; doi:10.1038/ejhg.2009.155; published online 14 October 2009
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INTRODUCTION
Family-based genetic research in isolated populations is an effective
methodology for identifying loci influencing variation in disease
traits.1,2 This approach has been used frequently to investigate genetic
mutations for specific hereditary disorders such as familial forms of
cancer and heart disease. Now, family-based study designs are also
being used on a much larger scale to investigate genetic predisposition
to diseases that have hitherto not been recognised as running in
families. As this approach is not as widely used at present as large
population-based studies, discussion of the ethical issues inherent in
genetic epidemiological research has largely focused on genomics and
biobanks3–8 and specifically on the tension between the promise of
important advances in biomedical research6,9 and the requirement for
robust ethical standards.7,10–12 New research techniques raise impor-
tant ethical issues relating to consent13–16 ownership, governance,
access to information, benefit sharing and community participation.
These issues apply partly to every kind of genetic study, but although
these issues are also applicable to family-based studies performed in
genetically isolated communities, the special characteristics of such
communities provide additional challenges to ethical approaches
designed for large population-based biobanks. For example,
safeguards designed to preserve participant privacy and confidentiality
in large population-based studies may be inadequate in small, isolated
communities.17,18 Within the context of family-based research in a
small community, standard procedures for anonymising participant
information19–21 may be inadequate for protecting the identities
of families. Furthermore, research in these isolated populations must
also address additional ethical issues. For instance, communities are
selected because they are genetically more homogeneous than non-
isolate populations, a criterion that is itself loaded with emotive
associations.22 On the one hand, such communities may be regarded
or may regard themselves as special or unique: on the other, there may
be derogatory associations with inbreeding or those being cutoff from
the world. These issues are of particular concern when the population
and/or specific pedigrees are described in scientific publications. As in
other genetic studies, family-based studies conducted in genetically
isolated populations can potentially uncover information about a
family’s health that may have wider implications for individual
members of that family, even if the individuals concerned were non-
participants. This is especially relevant when family trees are drowned
and where information about ancestries is collected. Those issues
need to be clearly communicated so that both families and individuals
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can make satisfactorily23 informed decisions about participation.
Several ethical–legal guidelines are available that specify the kinds of
information that should be provided in participant information
leaflets and informed consent forms to ensure that participants are
able to give satisfactorily informed consent. Examples include the
general guidelines of the Council for International Organizations of
Medical Sciences (CIOMS), and the guidelines of the National Office
of Public Health Genomics/Centers for Disease Control and Preven-
tion (CDC) and the Public Population Project in Genomics (P3G)
that specifically focus on genetic studies.24–26 Such guidelines are in
addition to national and local research ethics guidelines and legisla-
tion, which provide a roadmap for researchers compiling participant
information and consent forms. Yet, such guidelines tend to be very
general in scope and do not address the specific issues that apply to
genetically isolated populations.
The aim of this paper is to identify specific issues that should be
addressed and incorporated into participant information leaflets and
consent forms for family-based studies in genetically isolated popula-
tions. All the authors are working on different levels in genomic
studies in isolates, and although all the information leaflets and
consent forms for the five studies comply with national research
ethics requirements, they differ in many aspects. This led us to this
work. Taking the comprehensive CIOMS checklist of the international
guidelines (CIOMS G)25 as a starting point, we identified the topics
that, from our direct experience, needed to be addressed differently in
genetic isolates. Next, we compared the participant information and
informed consent forms of five European studies in genetically
isolated populations to identify what additionally needed to be
addressed.
METHODS
We used the International Ethical Guidelines for Biomedical Research Involving
Human Subjects of the CIOMS25 to examine the participant information of
studies in genetically isolated populations (see Supplementary information).
We reviewed the criteria one by one, in each case examining whether the topic
raises new concerns specific to family-based studies in isolates. We compared
the participant information and informed consent forms of five studies
participating in the EUROpean Special Populations reseArch Network (EURO-
SPAN). The studies are summarised briefly here, with further information in
Supplementary Appendix 1.
The Erasmus Rucphen Family study27 (ERF; the Netherlands) is a family-
based study that investigates the genetic origins of complex diseases in a
genetically isolated community in the south-west of the Netherlands. The study
population essentially consists of one extended family of descendants from 20
related couples that lived in the isolate between 1850 and 1900. All descendants
were ascertained, and descendants of age 18 years and older were invited to
participate. All participants underwent medical examinations and completed
several questionnaires.
MICROisolates in South Tirol (MICROS; Italy)28 is a family-based popula-
tion study that investigates the genetic origins of complex diseases. The
participants in the villages were selected on the basis of four criteria for
isolation: (i) evidence of an old settlement; (ii) a small number of founders; (iii)
high endogamy rates; (iv) slow or null population expansion and negligible
immigration. The expression ‘microisolate’ was used to distinguish small sub-
populations in remote, high valleys that have conserved an even higher degree
of isolation than the cultural and linguistic South Tyrolean isolate.
The Orkney Complex Disease Study (ORCADES; UK) is a family-based
study that seeks to identify the genetic factors influencing cardiovascular and
other disease risks in the population isolate of Orkney, an archipelago off the
north coast of Scotland. Individuals aged 16 years and over and with at least
one grandparent from the remote North Isles of Orkney were invited to
participate. As above, all participants underwent a variety of medical examina-
tions and provided information on health, lifestyle and family history of
disease.
The Northern Sweden Population Health Study (NSPHS; Sweden) is a
family-based population study that aims to identify genetic and environmental
risk factors for common, mainly non-communicable disease in populations
living in the arctic and sub-arctic areas. The study includes one population in
the southern part of the Swedish mountain range and one population located
in the extreme far north of Sweden on the border with Finland. All inhabitants
over the age of 15 were invited to participate. About 60% of those invited (740
individuals) participated in the study and underwent a comprehensive health
examination and sampling for serum, plasma and DNA analyses. Information
on genealogy, lifestyle, diseases and diet was collected.
The Croatian study (CROAS; Croatia)29,30 is a family-based study of
residents of small villages in a Dalmatian island. The village populations
of this and neighbouring islands in Croatia represent a well-characterised
meta-population of genetic isolates. The CROAS study investigated approxi-
mately 1000 unselected Croatian residents, aged 18–93 years, from villages on
the Dalmatian island. As above, each participant was examined for a large
number of disease-related traits and serum, plasma and DNA samples were
obtained.
RESULTS
Table 1 lists the topics from the CIOMS G that may raise additional
information requirements for family-based studies in isolated popula-
tions. The extent to which the participant information leaflets and
informed consent forms of the five studies already address these issues
is summarised below.
Selection of population
Item 1 of the CIOMS G states that individuals should be informed
about why they have been selected as suitable for the research. The
CIOMS G is silent on the selection of the population, as opposed to
the individual; however, for research in isolated communities, this is a
key issue. It is incumbent on researchers to explain the reason why the
population was chosen for the research, particularly when the selection
criterion is made explicit in future publications. Furthermore, the
population should be described in publications in a way that is not
stigmatising or in any other way harmful to participants or other
members of the community. Only MICROS and ORCADES explicitly
specify that the communities were selected for being more genetically
and environmentally homogeneous than the general population.
ORCADES contrasts the Orkney isles with urban populations,
where there is ‘a variety of occupations, lifestyles and ethnic back-
grounds,’ but is not explicit about the scientific reasons for choosing
the population. MICROS explains that historical studies were carried
out to identify suitable research populations and explicitly states
that the criteria used were high levels of endogamy and inbreeding,
low levels of immigration and the availability of good historical
information. ERF states that participants were invited if they were
descended from 20 couples living in the village between 1850 and
1900; however, the reason why the descendants of these couples were
of interest is not made explicit. ORCADES and ERF do not assess all
inhabitants of the community and both specify that only a selection
was invited, but they do not specify why that selection was made.
NSPHS states that the study aims to investigate the health of those
living in the arctic and sub-arctic regions, giving both environmental
and historical reasons for population choice: settlements of long
standing with stable populations, little immigration and traditional
lifestyles were chosen.
Consent to participate
Informed consent is a requirement for every research conducted on
human subjects, based on the notion of autonomy of the subject who
has the right to decide. An intervention in the health field may only be
Participant information in genetic isolates
D Mascalzoni et al
297
European Journal of Human Genetics
carried out after the person concerned has given free and informed
consent to it. As defined by the Council of Europe,31 informed consent
is ensured through appropriate information about the purpose and
nature of the intervention as well as on its consequences, benefits and
risks. This freedom does not end with the provision of consent and, in
fact, the person concerned may freely withdraw consent at any time. In
genomics studies in general, it is very difficult to foresee every possible
development of research. This means that the consent to participate in
Table 1 Review of the appropriateness of Council for International Organizations of Medical Sciences (CIOMS) guidelines checklist (G):
additional concerns that apply to family-based studies in isolated populations
CIOMS G
Key issues and additional informational requirements for family-based studies in genetically isolated populations.
Selection of population (G1)
Defining a population as an isolate could be stigmatising if not defined clearly.
There may be a mismatch between the way in which a population is described in participant information leaflets and the way it is subsequently described in scientific
publications.
The reasons that the population is considered suitable for the research should be made explicit and this information should be consistent between the participant
information sheet and any future publications.
Withdrawal of consent (G2)
There may be technical problems in withdrawing all data on a single individual.
Withdrawal of single individuals may have consequences for collected family data.
Participants may feel under additional pressure from family members to participate or not participate in the study.
The right to withdraw from the study can only be meaningful if people are updated about major changes in the direction of the project.
Researchers should make clear what will happen to the data relating to withdrawn participants, including genealogical data.
Information leaflets should state clearly that participation is an individual decision but also that this may have implications for the rest of the biological family.
Major changes in project direction should be communicated to participants so that they are able to re-evaluate their decision to participate.
Research purpose (G3)
Participants may not be aware that researchers routinely verify pedigree relationships using genetic information. Crucially, this could potentially provide researchers with
information, which may contradict that provided directly by the participants – for example, on paternity.
It should be made clear that the research is on extended families. The implications of this should be clearly explained: this means that family trees will be reconstructed
and that pedigree relationships will be verified using genetic information.
Benefit sharing (6)
There is greater potential to direct benefits to the study population and to involve the population in decisions about benefit sharing because the study populations are small
and well defined, in contrast to large, dispersed, population-based studies.
Researchers should engage with the community regarding the types of benefits that might accrue and those that would be welcomed.
Potential risks of (G9) participation
There are potential informational risks to participants’ family members and to the wider community, whether or not they are themselves participants.
The potential risks to participants, their families and the wider community should be clearly explained, including learning about family illnesses, increased insurance
premiums, disclosure of non-paternity, community anxiety about specific disease risk, and the use of data for criminal investigations.
Expected benefits of research (G11)
Research projects in small, isolated communities typically have a high profile, which may easily lead to unrealistic expectations as to what the study might find and what
benefits might flow from this.
Care must be taken not to make unrealistic claims about the benefits likely to accrue to the community from the study.
Privacy concerns (G14)
Standard safeguards are insufficient to guarantee privacy, not just for the single individual but for the whole biological family. Through combined data (genealogies, health
data, genotypes), families and individuals in the family may be identifiable.
There is a need to be open about the difficulties of guaranteeing complete privacy and to ensure that if a publication might potentially identify individuals and families,
fully informed consent is obtained from those individuals and families before publication.
Disclosure of genetic data (G16)
Linked genetic, genealogical and health data can provide information about all members of the biological group, including non-participants.
There may be legal requirements to disclose data to the police, courts or other third parties in certain circumstances.
Families and individuals are more easily identifiable in small, close-knit communities than in more anonymous populations.
Researchers must state under what circumstances genetic information will be shared with external agencies (research partners, official agencies).
Information sheets should clearly state the policy according to the current law, for example, that data will not be disclosed to police/court unless there is a court order.
In publishing study findings, researchers must take great care not inadvertently to identify families through indirect information (‘the family in the study village with three
affected childreny’).
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a project based on transparent and complete information needs to be
implemented on the basis of this fact. For this reason, many of the
points raised in the discussion aim at ensuring a proper and
transparent communication with the participants to allow a free
choice.
Withdrawal of consent
The right to withdraw (CIOMS G article 2) is enshrined in every type
of research on human participants.25,31 It is, however, a particularly
sensitive issue in this context, entwined as it is with issues of privacy
and confidentiality, not just for the individual participant but also for
non-participating relatives, as genetic information is shared by the
biological pedigree. So first, in a small community, participants might
feel pressurised either to participate or not to participate by family
members or others in the community. The key issue, however, is the
lack of clarity about what withdrawal of study participation actually
means, especially when the family as a whole is an essential source of
information in family-based studies. Withdrawal can refer to the
destruction of personal information, destruction of the whole set of
data about an individual including anonymised data, or the destruc-
tion of the specimens as well.17,32 The precise details of what will
happen to the data and samples of participants who have withdrawn
from the study are often not specified. In practical terms, anonymised
data or shared data16 may be difficult or impossible to destroy, and
data that have already been analysed are not completely destroyable,
especially if linked in a characterised genealogical tree.12,33 If, for these
reasons, complete withdrawal from the study is not possible, this
should be made explicit at the outset. Finally, the right to withdraw
consent can only be meaningful if participants are kept up-to-date
about any changes in the purpose or direction of the study. The only
leaflet to comment explicitly on potential family or community
pressure on individuals to participate is the ERF one, which states
that participation is an individual decision and that individuals should
not feel guilty towards their relatives because of the decision they
make. Regarding participant withdrawal, all studies except CROAS
state that participants are free to withdraw at any time without giving
any reason. ORCADES and CROAS give no information on what
happens to data and samples if a participant withdraws. MICROS
states that data will either be removed from the study or completely
anonymised, where removal is not possible (as, for instance, in shared
data), and samples destroyed. ERF states that data and biological
samples will be removed. The NSPHS study states that withdrawal
implies destruction of the samples, but is unclear about what happens
to data in these circumstances. None of the studies mentions what
happens to genealogical data if participants withdraw.
Research purpose
Item 3 of the CIOMS G specifies that individuals should be informed
about the purpose of the research. Genetic studies in isolated com-
munities aim to unravel the contribution of genetic factors in
common diseases, but in contrast to population-based cohort studies,
they do this using genealogy data. We agree that participants should be
informed that family trees will be reconstructed on the basis of
genealogy data, which implies that pedigree relationships can be
verified using genetic data, but that data on genealogies will neither
be shared nor disclosed. Crucially, participants must be informed that
this provides researchers with information that may contradict that
provided by the participants themselves (eg, on paternity). ORCADES
describes ‘tracking the inheritance of genes in families’ but is not
explicit about tracing family trees. CROAS and ORCADES do not
mention family tree reconstruction, although this is clearly implied, as
a genealogical form is attached for participants to complete. MICROS
and ERF state explicitly that family trees are reconstructed, but neither
explains that this might potentially reveal non-paternity or how such
sensitive information will be treated.
Benefit sharing
The CIOMS states that researchers must provide information on
whether money or other remuneration will be provided in return
for the individual’s participation (item 6) and on whether participants
will benefit from any commercial products developed as a result of the
research (item 20). Again, the CIOMS G is explicit only about sharing
benefits with individuals, not communities; however research in non-
isolate populations offers the potential to direct benefits to the study
population and to involve the population in decisions about benefit
sharing. Although few if any commercial benefits are anticipated as a
result of this type of study, the fact that these studies are located in
small, well-defined communities means that were commercial benefits
to accrue, and that it would be much easier to share the proceeds with
the community than it would be in a bigger study. Accurate informa-
tion about the potential financial gains and transparency about who
will benefit is essential to create realistic expectations.3,11,24,34,35 Many
studies show that participants are generally interested in knowing this
information; however, this would not necessarily make a difference to
their decision to participate.36,37
The MICROS information leaflet states that although no commer-
cial benefits are anticipated, any that are forthcoming will be rein-
vested in research and health facilities in the region but that there will
be no individual benefits to participants. The CROAS information
leaflet mentions the possibility of the commercial use of study results
but does not mention benefit sharing or financial benefit to the
community. The ERF information sheet does not mention benefit
sharing. The ORCADES consent form explicitly states that partici-
pants will not benefit financially if the research leads to the develop-
ment of new treatments or medical tests, but no mention is made of
community financial benefit. In the NSPHS study, although commer-
cial applications were discussed at community information meetings,
this subject was not included in the informed consent form.
Potential risks of participation
Article 9 of the CIOMS G specifies that participants be informed
about any foreseeable risks, pain, discomfort or inconvenience arising
from participation, including risks to the participant’s spouse or
partner. In the context of family-based research in isolated popula-
tions, there are potentially significant informational risks to partici-
pants’ family members and to the wider community – including non-
participants. These include learning about family illnesses, increased
insurance premiums, disclosure of non-paternity and community
anxiety about specific disease risks.
The CROAS study does not mention any potential risks. MICROS,
ORCADES and ERF mention only the potential physical risks of
participation (eg, bruising at the site of venepuncture), but no risks
associated with unanticipated information. NSPHS discusses the risks
with the community before the start of the study but does not go into
detail in the information leaflet. None of the information leaflets
identifies misuse of data, non-paternity disclosure, community stig-
matisation or family conflict as potential risks, despite the fact that
pedigrees and individual health and genotype data are held and used.
Expected benefits of research
Article 11 of CIOMS G specifies that participants should be informed
about the expected benefits of the research to the community or
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society in general or to scientific knowledge. The expected benefits to
society are generally indirect, as this kind of research does not provide
new cures or results that are of immediate use to the population. In
small, isolated communities, where the research project has a high
profile, it is important not to create false expectations as to what the
study might find and what benefits might flow from it. MICROS
makes a very general statement about the possible future health
benefits following from new knowledge gained through the study.
CROAS and ORCADES imply a benefit to the local community,
stating that the study may uncover information that may improve
the community’s health. ORCADES, NSPHS and ERF mention the
thorough health examination as an individual benefit, with the
potential of alerting participants’ general practitioners about unex-
pected incidental findings. CROAS suggests that the project may
improve the health of the island but does not state how this might
happen. In general, the information leaflets take a very narrow view of
the potential benefits to participants, when in fact this type of study
can have many very positive, if less obvious, spin-offs for participants.
NHPHS and ORCADES, for example, have conducted various meet-
ings and lectures with a health promotion/educational focus and ERF
has conducted annual information meetings to inform general practi-
tioners about the preliminary results. These approaches have been
valuable in building trust between the participants and the scientists,
in addition to the health promotion benefits. ERF participants have
received several information leaflets with information about the study
progress and also been invited to an information meeting at the end of
the data collection period. NHPHS has found that focusing on the
village has provided a boost to the community, enabling them to see
themselves as part of a larger European project. In south Tyrol, the
publication of two historical books about genetics and the history of
the population proved a very popular way of feeding back some of the
results to participants. For some, participation has also led to the early
diagnosis of medical problems.
Privacy concerns
The CIOMS G specifies that participants must be informed about the
arrangements for safeguarding their privacy and the confidentiality of
records (article 14). The privacy of individual genetic data is a key
concern19,33,38,39 because of the potential discriminatory consequences
of misuse of such data by insurance companies, health-care providers
and so on (examples of this misuse may be uninsurability, or having to
pay a higher price if carriers of certain gene etc20). Even if data are not
directly identifiable, the possibility of cross-matching data with
individuals cannot be ignored: in small, isolated communities, stan-
dard: safeguards may be insufficient to guarantee privacy, both for
individual participants and for their families. Unusual families may be
identifiable through a combination of genealogical, genetic and health
data. Although in some communities the genealogical information is
in the public domain, such data must be regarded as personal
information under the European Privacy Law, particularly in the
scientific research context, where genealogical data are systematically
collected by professional researchers and cross-linked with medical
and genetic information. The resulting data may be very different
from socially known genealogies, raising issues of data confidentiality
and security as well as presenting practical difficulties for participant
withdrawal as described above. The release of such highly sensitive
information may be disruptive for a small community, with the
potential of uncovering information on, for example, false paternities
and undisclosed adoptions. Enhanced genealogies should, therefore,
be stored securely and confidentially. Although all countries have strict
laws governing the handling and storage of personal data and these
issues were often discussed in meetings with the communities, they
tend not to be addressed at length in the information leaflets. The
MICROS information leaflet states that data will be handled in
accordance with the Italian Privacy law, which also means the
separation of health data and genealogies from personal data. The
only information leaflet to mention the risk of identification of
participants in publications is that of the ORCADES study and this
states that individuals will not be identifiable in any way in research
publications; however, this may be a problematic point as it is hard to
guarantee this 100% in studies of this kind.
Disclosure of genetic data
Article 16 of the CIOMS G states that researchers must inform
participants about their policies regarding the disclosure of personal
and familial genetic data to third parties. This is important because in
family-based genetic research, genealogies linked to genetic data may
contain information about non-participants, which may be useful to a
range of external agencies and which researchers may be legally
obliged to hand over in certain situations. For example, in the UK,
data must be disclosed if there is a court order authorising this (as in
the case of crimes, even minor ones, or if there is the need to assess
facts relevant to public security). Article 16 also has implications for
the publication of research findings in scientific journals. In small,
close-knit communities, individuals with genetic conditions can
potentially be identified from very little information (‘the family in
the study village with three affected childreny’) and information can
spread very quickly and affect family life more strongly than in more
anonymous environments. Publication policies for this type of study
must, therefore, first ensure that individual and family identities are
anonymised wherever possible, and second, that where this is not
possible, consent to publication is obtained from the individuals and
families concerned.
Although most of the information leaflets state that data will be
shared only with research partners or collaborators, these terms are
not clearly defined and neither are the arrangements for the safe
exchange of data made explicit.40 The MICROS and ERF studies state
that anonymised data will be shared with research partners for specific
research purposes only. The ERF leaflet explains that research partners
will only have access to coded data. The CROAS information leaflet
mentions that data will not be shared with anyone outside the research
team. In the meetings before the initiation of the NSPHS study, it was
made clear that the study was part of a wider collaboration; however,
this information is not included in the information leaflet. ORCADES
states that data will not be made available to any other authorities.
None of the studies mentions police/court access to data, which is an
issue in some but not all countries (Italy’s strict privacy laws, eg, mean
that such data cannot be obtained by the courts).
Table 1 summarises what we regard as essential information to
ensure adequate informed consent for family-based studies in isolates.
DISCUSSION
We reviewed the information and informed consent forms of five
family-based studies in genetically isolated populations following the
CIOMS G and showed that the existing guidelines may not be fully
appropriate for these types of studies to deal with all the issues that are
relevant to this kind of studies. Before discussing the implications in
more detail, two points need to be addressed. First, it is important to
emphasise that the information leaflets and consent forms of all five
studies complied fully with national research ethics requirements in
the five nations concerned. This review highlights additional issues
specific to family-based genetic studies in isolated populations that we
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feel are not adequately addressed by the existing national and
European ethics guidelines. These are raised with the aim of trying
to improve recognised best practice and international guidelines for
the conduct of these studies. Our review of the CIOMS checklist
selects only those topics that may raise additional issues specific to this
type of study. We did not compare generic topics that are relevant to
all genetic medical studies10,12,41 (eg, information on the funding of
the research, the ethical review process, disclosure of data in society
and genetic discrimination).7,10,41 Second, most topics that were not
addressed in the information leaflets may have been communicated in
other ways by the studies, for example, in information meetings and
brochures and in face-to-face discussions between individual partici-
pants and research staff. This greatly helped provide transparent and
careful information and was greatly appreciated by the communities.
This also highlights the central importance of other forms of com-
munication with participants and communities.
Several interesting points follow from our comparison. First, we
observed that there is often a discrepancy between the research
purpose as it is described in scientific publications and how this is
communicated to potential participants in information and consent
documentation. In general, there was scant explanation as to why
these specific populations were invited to participate. Hardly any of
the studies mentioned the term ‘genetically isolated population’ or
referred to endogamy or inbreeding, and yet these descriptions are
used by researchers in scientific publications. These are highly sensitive
issues that could potentially affect the communities concerned. To
some extent, discrepancies between the way research aims are com-
municated to participants and to the scientific community may be
attributable to the difficulties in communicating complex scientific
concepts to a lay audience; to some extent, they reflect the fluidity of
research aims that often evolve over time in a fast-moving field. It is
obviously important, however, to ensure that these discrepancies do
not arise because of the researcher’s fear that providing full informa-
tion on research aims might have a detrimental effect on participation
rates.
Second, when addressing the implications of participation, most
studies identified minor physical consequences or potential benefits of
having a personal health check. Little or no emphasis, however, was
given to the potentially more significant consequences of participa-
tion, most notably the possible informational implications, both
positive and negative, for both individuals and families, such as
discovering new information about family health, especially in an
easily identifiable community.15,20,42–44 It may be that participant
information leaflets are not an adequate means of addressing this
type of information, but if this is the case, it raises the question as to in
what way and at what stage of the process this issue should be
addressed.
Third, all studies mentioned that participants’ personal information
is stored under a code that provides a reasonable guarantee of not
being traceable back to personal data. Complex family trees are not,
however, completely anonymous and can lead to the dissemination of
personal and family health information of an extremely sensitive
nature if cross-matched with other data, for example, when presented
in scientific publications. Clearly, researchers should be aware that
family trees could be recognised if steps are not taken to anonymise
them and that this has consequences for the confidentiality of the
accompanying medical information.
Fourth, the potential stigmatisation of communities is an issue that
demands consideration in studies of this type. Perceptions of risk vary
greatly between localities and this is reflected in different policy
approaches, for example, regarding disclosure of information in
publications.45,46 This is also the case in the EUROSPAN study
populations: for example, the MICROS publication policy states that
individual villages should not be named in any publication where this
might result in stigmatisation (name of illness result related to specific
villages), but can be named in more neutral publications (general
description of the institute and of the scopes of research). Similarly,
ORCADES publications do not identify individual isles, except in
papers that are purely investigating the population sub-structure
within Orkney. In the NSPHS study, participants and potential
participants expressed a concern that single pedigrees should not be
revealed or used in any publication, because of the risk of identifying
specific families in such a small community. In contrast, a technical
CROAS publication provides the inbreeding coefficient data of named
villages. The ERF community name is included in the project’s
acronym, which is widely used in publications and elsewhere. In the
internet era, accessing specialist publications across national borders is
increasingly easy, and maintaining different publication policies may
be problematic for international collaborators and could potentially
raise serious issues of trust. For example, the failure to discuss the issue
of inbreeding at the consent stage might make researchers vulnerable
to a charge of lack of transparency if participants access publications
whose focus is the inbreeding coefficient.
Fifth, this review has highlighted the importance of communication
as a process that starts before the project commences, continues
through the information and consent stage, and is ideally carried on
throughout the project through to the dissemination of study findings.
This is consistent with the findings of qualitative work on perception,
which have found that study participants actively seek more informa-
tion about research processes and results.47–49 Web pages, printed
newsletters, regular meetings with participants or update letters to
individuals are all useful means of keeping in touch, particularly in
such a fast-moving research field. Keeping channels of communication
open throughout the life of the project is clearly essential if satisfacto-
rily informed consent is to be achieved.16,50
Finally, our research highlights the importance of the community,
alongside the individual, in this type of research. Linking genealogical,
health and genetic data in a small, isolated community provides
researchers with information not just about individual participants
but also about the whole biological group – participants and non-
participants alike. The implications for and rights of non-participants
in this type of study are dimensions that are missing in current
research guidelines, but it is essential that researchers working in
family-based genetic studies in isolated populations engage with the
wider community so that non-participants are also aware of the
possible implications of the study and given an opportunity to
make their voices heard. It is important to reiterate that although
we have concentrated fairly narrowly here on the information given to
participants through the information and consent stage of the project,
many of the issues raised here were addressed by all our projects at
other stages, starting from discussions with research ethics committees
at the project inception stage, through to public meetings and one-to-
one communications with individual participants later on. From this
review, it is clear that generic guidelines cannot adequately address all
the ethical issues of this type of study yet. Differences between studies
and populations may require that specific topics be added to the
information leaflet to ensure that participants have the information
they need to make an informed decision. Nevertheless, we have
identified a group of issues that merit special attention in all these
types of study and should be addressed not only in the studies (special
Information procedures, more comprehensive information leaflets
and so on) but also on a normative level. International collaborations
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face additional challenges resulting from national differences in ethical
norms and procedures, which can result in different standards and
requirements.18 Therefore, there is a need for a harmonising approach
for research in isolates that is equally applicable in different national
contexts. The results of this analysis should not be seen as a definitive
set of guidelines for family-based research in isolated communities but
rather as a first step at raising some important issues that can then be
taken forward in the public arena.
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